SynthesisFrontiers in immunology2026
Efficacy and safety of tumor necrosis factor-α inhibitors and mesenchymal stem cells in the treatment of fistulizing Crohn's disease: a systematic review and network meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumor necrosis factor-α inhibitors (anti-TNF-α) and mesenchymal stem cells (MSCs) have been proven to be effective for Perianal fistulizing Crohn's disease (PFCD). However, no head-to-head clinical trials have directly comparing these two therapies. Therefore, using a network meta-analysis and systematic review, we evaluated the efficacy and safety of anti-TNF-α and MSCs in PFCD patients. Methods: We included randomized controlled trials (RCTs) evaluating anti-TNF-α or MSCs against placebo (PBO) in PFCD patients. The primary efficacy outcomes were fistula remission and fistula response. The secondary outcome was clinical remission. Safety outcomes comprised adverse events and infections. Effect sizes were reported as odds ratios (ORs) with 95% credible intervals (CrIs). Treatment rankings were determined using the surface under the cumulative ranking curve (SUCRA). Results: A total of 15 RCTs involving 2, 475 patients were included. Compared with PBO, MSCs significantly improved fistula remission (OR = 5.33, 95% CrI: 2.19-19.03) and fistula response (OR = 4.76, 95% CrI: 1.78-20.37). Anti-TNF-α also significantly increased fistula remission rates (OR = 2.19, 95% CrI: 1.01-4.54). SUCRA rankings placed MSCs first for both fistula remission (SUCRA = 0.97) and fistula response (SUCRA = 0.967). For clinical remission, anti-TNF-α demonstrated superior efficacy (OR = 2.41, 95% CrI: 1.30-5.03) compared with MSCs (OR = 1.71, 95% CrI: 0.69-5.57) and PBO. Indirect comparisons revealed a non-significant trend favoring MSCs over anti-TNF-α for fistula remission (OR = 2.44) and fistula response (OR = 2.55). Neither treatment showed statistically significant differences in adverse events or infections versus PBO, indicating favorable safety profiles for both. Conclusion: In indirect comparisons, MSCs showed a numerically greater but not statistically significant effect on fistula healing compared with anti-TNF-α, whereas anti-TNF-α was superior for clinical remission. Both treatments were generally safe. Given the indirect nature of these comparisons, direct head-to-head trials are needed to establish their comparative efficacy. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/recorddashboard, identifier CRD42021283052.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.